Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
2.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica;
2024 Jan 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38268449
3.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Hematol Oncol;
42(3): e3274, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38711253
4.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
5.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
N Engl J Med;
380(8): 720-728, 2019 02 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30786186
6.
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
Haematologica;
107(4): 984-987, 2022 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34937320
7.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J;
13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37726298
8.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol;
10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36400069
9.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
J Clin Oncol;
41(5): 1035-1045, 2023 02 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36395435
10.
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Clin Lymphoma Myeloma Leuk;
22(2): 121-128, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34674981
11.
Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
Leuk Lymphoma;
62(4): 791-800, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33243049
12.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Clin Lymphoma Myeloma Leuk;
20(11): e910-e925, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32912820
13.
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
EJHaem;
4(1): 301-304, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36819162